NASDAQ : JAZZ

Jazz Pharmaceuticals plc

$252.86 USD

-$5.52 (-2.14%)

Volume
561.21K
Average Volume
870.77K
Market Capitalization
$15.88B
P/E Ratio
616.73
Dividend Yield
0.00%
Price Target
$260.00
Year High
$261.30
Year Low
$105.00
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$2.04
Company Overview

NASDAQ

Renee D. Gala

Biotechnology

Healthcare

JAZZ

2890

IE

USD

https://www.jazzpharma.com

353 1 634 7800

G50871105

0001232524

Liquidity Metrics

1.20

2.04

1.85

0.82

0.00

Sales & Valuation

$4.27B

3.58

3.45

12.75

20.12

Profitability

-$5.84

-$356.15M

0.66%

-4.93%

0.71%

0.25%

P/E Metrics

616.73

-2.09

-2.09

Analyst Price Target & Rating

$260.00

$307.00

$229.00

Neutral

3/5

48 Analysts

-2.75%

Financial Health Scores

2.02

6/9

$2.34B

$11.86B

$7.33B

-$14.39M

Key Metrics (TTM)

$19.46B

4.38

35.76

2.04

0.71%

-0.62%

0.19%

7.84%

$28.02

243 days

Company Executives
Name Title
Renee D. Gala President, Chief Executive Officer & Director
Bruce C. Cozadd Co-Founder & Chairman
Philip L. Johnson Executive Vice President & Chief Financial Officer
John D. Bluth Head of Investor Relations
Thomas J. Riga Senior Vice President & Chief Business Officer
Heidi Manna Executive Vice President & Chief People Officer
Patricia Carr Senior Vice President & Chief Accounting Officer
Neena Patil Executive Vice President & Chief Legal Officer
George Christopher Eliades Senior Vice President & Chief Transformation Officer
Jed Black Senior Vice President of Sleep & CNS Medicine
John Miller Senior Vice President of Corporate Strategy
Samantha Pearce Executive Vice President & Chief Commercial Officer
Robert Iannone Executive Vice President, Chief Medical Officer and Global Head of Research & Development
Poll Results

No votes yet today — be the first to share your view!

About Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harb ... oring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Aristotle Global Equity Advisory Q2 2026 Portfolio Review

2026-07-30 01:20:00

For the second quarter of 2026, Aristotle Capital's Global Equity WM Composite posted a total return of 6.92% pure gross of fees (6.40% net of fees), underperforming the MSCI ACWI Index, which returned 14.93%, and the MSCI World Index, which returned 13.76%. During the quarter, we sold our positions in Danaher, Dolby Laboratories, and Tokyo Century and purchased Techtronic Industries and Wal-Mart de Mexico. Munich Re, the world's largest reinsurance company, was a detractor during the quarter.

Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term

2026-07-28 10:41:15

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth

2026-07-27 11:03:08

Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is JAZZ Still the Best Cannabis Stock After Federal Rescheduling?

2026-07-24 09:56:36

Jazz Pharmaceuticals pairs its FDA-approved CBD blockbuster with a diversified drug portfolio, offering medical cannabis exposure despite ongoing pipeline risks.

These major drug stocks rally after Trump's zero tariff announcement

2026-07-22 06:31:14

President Donald Trump has announced that all generic drugs imported into the United States would continue to enjoy a zero-percent tariff for another two years, sending major drug stocks up.

Will Jazz (JAZZ) Beat Estimates Again in Its Next Earnings Report?

2026-07-21 13:11:09

Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026

2026-07-20 16:15:00

DUBLIN, July 20, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 second quarter financial results on Monday, August 3, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m.

iShares Russell 2000 Value vs. Morningstar Small Cap: Which ETF Suits Your Portfolio Best?

2026-07-07 07:40:01

IWN delivered a 37.4% one-year return but carries higher fees, while ISCV offers a 0.06% expense ratio and stronger dividend yield of 1.9%.

Frequently Asked Questions

What is the current Jazz Pharmaceuticals plc (JAZZ) stock price?

Jazz Pharmaceuticals plc(NASDAQ:JAZZ) stock price is $252.86 in the last trading session. During the trading session, JAZZ stock reached the peak price of $261.3 while $105 was the lowest point it dropped to. The percentage change in JAZZ stock occurred in the recent session was --2.14% while the dollar amount for the price change in JAZZ stock was -$5.52.

JAZZ's industry and sector of operation?

The NASDAQ listed JAZZ is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of JAZZ?

Renee D. Gala | President, Chief Executive Officer & Director
Bruce C. Cozadd | Co-Founder & Chairman
Philip L. Johnson | Executive Vice President & Chief Financial Officer
John D. Bluth | Head of Investor Relations
Thomas J. Riga | Senior Vice President & Chief Business Officer

How many employees does JAZZ have?

Number of JAZZ employees currently stands at 2890. JAZZ operates from Waterloo Exchange, Dublin, DU D04 E5W7, IE.

Link for JAZZ official website?

Official Website of JAZZ is: https://www.jazzpharma.com

How do I contact JAZZ?

JAZZ could be contacted at phone #353 1 634 7800 and can also be accessed through its website. JAZZ operates from Waterloo Exchange, Dublin, DU D04 E5W7, IE.

How many shares of JAZZ are traded daily?

The average number of JAZZ shares traded daily for last 3 months was 870.77K.

What is the market cap of JAZZ currently?

The market value of JAZZ currently stands at $15.88B with its latest stock price at $252.86